12:00 AM
 | 
Feb 16, 2015
 |  BC Week In Review  |  Clinical News  |  Clinical Results

ACH-3102: Additional Phase II data

Additional data from 12 treatment-naive patients with HCV genotype 1 infection in the open-label, partial-crossover Phase II proxy study showed that once-daily 50 mg ACH-3102 plus 400 mg Sovaldi sofosbuvir for 6 weeks led to an SVR 12 weeks after the end of treatment in...

Read the full 212 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >